Olalla
Maroñas Amigo
Publicaciones (43) Publicaciones de Olalla Maroñas Amigo
2025
-
A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines
International Journal of Molecular Sciences, Vol. 26, Núm. 17
-
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
Frontiers in Pharmacology, Vol. 16
-
Differences in DPYD Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study
Pharmaceuticals, Vol. 18, Núm. 4
-
Exploring the sensory profile and pharmacogenetic biomarkers in child and youth ADHD patients undergoing methylphenidate (MPH) treatment: a systematic review conducted in European studies
Journal of Psychiatric Research, Vol. 190, pp. 512-521
-
Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations
Scientific Reports, Vol. 15, Núm. 1
-
Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients
Biomedicines, Vol. 13, Núm. 3
-
The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review
Pharmaceuticals, Vol. 18, Núm. 5
-
The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
European Psychiatry, Vol. 68, Núm. 1
2024
-
Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition
Schizophrenia Research, Vol. 268, pp. 302-307
-
Developments in pharmacogenetics, pharmacogenomics, and personalized medicine
Pharmacological Research, Vol. 200
-
Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies
Schizophrenia Research, Vol. 268, pp. 293-301
-
Farmacogenética
Medicina interna (Elsevier España), pp. 1284-1291
-
Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 135
-
Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives
Drug Metabolism and Personalized Therapy, Vol. 39, Núm. 4, pp. 183-199
-
Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling
Psychiatry Research, Vol. 333
2023
-
Deletion of the CYP2D6 gene as a likely explanation for the serious side effects of the antipsychotic drug pimozide: a case report
Frontiers in Pharmacology, Vol. 14
-
Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Investigative ophthalmology & visual science, Vol. 64, Núm. 13, pp. 34
2021
-
Genetic diversity of drug-related genes in native americans of the brazilian amazon
Pharmacogenomics and Personalized Medicine, Vol. 14, pp. 117-133
-
Long runs of homozygosity are associated with Alzheimer’s disease
Translational Psychiatry, Vol. 11, Núm. 1
-
Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics
Pharmaceutics, Vol. 13, Núm. 7